Lilly adding two more insulin options to discount program
Under fire over insulin prices, the Indianapolis-based drugmaker said Tuesday morning it is introducing lower-priced versions of its Humalog KwikPen and Humalog Junior KwikPen.
Pharmaceutical
-
$1.1B acquisition would give Lilly more skin in immunology game
Analysts have said that Dermira’s lead pipeline product, lebrikizumab, has the potential to be the best in class among a wave of similar antibodies to treat eczema.
Read More -
Eli Lilly to spend $400M on manufacturing expansion in Indy, add 100 jobs
The pharmaceutical giant says it needs additional manufacturing capacity to keep up with demand for current medicines and new drugs expected to emerge from its pipeline.
Read More -
Lilly earns more than expected but misses revenue expectations on key drugs
Eli Lilly and Co. easily topped earnings expectations in the third quarter, but shares in the Indianapolis-based drug company tumbled nearly 5 percent Wednesday morning.
Read More -
Lilly’s hot-selling Taltz approaching blockbuster status
Last year, Taltz rang up sales of $937.5 million, and doctors are increasingly prescribing it. For the first six months of this year, Taltz recorded $606.3 million in sales, putting it on pace to break the $1 billion threshold, perhaps in the third quarter.
Read More
Articles
North America trade pact contains rare setback for Big Pharma
To satisfy House Democrats, the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less expensive knockoffs.
House passes bill to empower Medicare to negotiate drug costs
The legislation has no chance of passing the Republican-controlled Senate, and the White House has issued a veto threat. Still, Democrats saw a victory in the message their bill sends to voters.
U.S. report: Prescription drug prices down slightly last year
Though modest, it was the first such price drop in 45 years, according to nonpartisan economic experts at the federal Department of Health and Human Services, who deliver an annual report on the nation’s health care spending.
Pelosi sets Medicare showdown on drug costs, new benefits
As a hammer to force companies to negotiate, House Speaker Nancy Pelosi would impose steep sales taxes on the medications at issue. Overall, budget analysts estimated the legislation would cut industry revenues by $500 billion to $1 trillion over 10 years.
Medicare drug plan finder can steer seniors to higher costs
As open enrollment goes into the home stretch Thanksgiving week, critics say the new tool can create confusion by obscuring out-of-pocket costs that seniors should factor into their decisions.
White House urgently ramps up push for drug cost legislation
A Gallup-West Health poll finds that 66 percent of adults don’t believe the Trump administration has made any progress, or very much progress, in limiting the rising cost of prescription drugs.
Source: White House finds Pelosi drug plan ‘unworkable’
President Trump is instead backing a bipartisan bill that would for the first time limit what seniors have to pay out of their own pockets for medications.
Walgreens to close in-store clinics, add Jenny Craig sites
The company said Monday that it will close 150 Walgreens-run clinics by the end of the year, but it will keep open more than 200 that are run in partnership with health care providers.
Eli Lilly CEO says drugmaker won’t rehash old Alzheimer’s data
Digging through old data to salvage a seemingly failed Alzheimer’s drug paid off big time for Biogen Inc., but at least one of its rivals has no plans to follow suit.
Trump, Pelosi still working on drug-pricing deal despite impeachment drama
President Donald Trump and House Speaker Nancy Pelosi could hardly be more at odds—but behind the scenes, they’re still grasping at a bipartisan deal to lower the cost of prescription drugs.
Indiana sues distributors in opioid epidemic
One day after three opioid distributors reached a $260 million tentative settlement with two Ohio counties, Indiana Attorney General Curtis Hill filed a lawsuit seeking damages from the same three companies.
In surprise turnaround, new analysis finds Alzheimer’s treatment might work
Seven months after clinical trials for a promising Alzheimer’s drug were halted and the treatment was declared a failure, a new analysis suggests it was actually effective, and the company that makes it plans to move forward in securing federal approval.
Nation’s top drug distributors reach $260M deal to settle opioids lawsuit
The settlement means a high-profile trial in Ohio will not move forward, but it does not resolve more than 2,600 other lawsuits across the country seeking to hold the drug industry accountable for a crisis that has been linked to more than 400,000 U.S. deaths since 2000.
Opioid settlement talks broaden ahead of first federal trial
Outlines of a settlement call for $22 billion in cash over time plus up to $15 billion worth of overdose antidotes and treatment drugs, with distribution of those drugs valued at another $14 billion.
Lilly experimental drug fails in late-stage trial for pancreatic cancer
The drug, called pegilodecakin, had been seen as a promising treatment for one of the deadliest types of cancer, and was the lead product in Lilly’s $1.6 billion acquisition of Armo BioSciences last year.
VP Pence says Indiana has ‘a lot to gain’ from new North American trade deal
Vice President Mike Pence stumped for President Trump’s proposed deal with Mexico and Canada during a rally Thursday at McAllister Machinery on the city’s southeast side.
Pace planning 200-acre life-science business park by airport
The owner of Pace Air Freight, which specializes in truck transport of pharmaceutical products, is in the process of assembling land it doesn’t already own, including parcels owned by Indianapolis International Airport.
Indiana joins states seeking to settle with Purdue Pharma
Indiana Attorney General Curtis Hill is among the 29 attorneys general across the country backing a proposed settlement with OxyContin maker Purdue Pharma, calling the agreement a “significant breakthrough in our important fight against the opioid crisis.”
Pharmacy owner sentenced to 33 months for making over-potent drugs
Paul Elmer, 68, of Fishers, was sentenced Wednesday in U.S. District Court in Indianapolis, six months after a jury found him guilty of nine counts of adulterating compounded drugs and one count of conspiracy.